Member Info for BabyHuey

according to LinkedIn they have 6 employees

https://www.linkedin.com/company/check-diagnostics-gmbh/people/

But there are 14 people named on the website, regardless it's a tiny mom&pop outfit. The potential revenue is pennies.

Also concerned that there is no effort to rebrand as Novacyt

value of patents included in fair value est. NCYT haven't done m&a for years, they haven't done r&d for a while because of Covid, what patents do NCYT have that people want? that's why NCYT needs to do m&A or r&d to get products to sell that people want so NCYT can stop losing money.
At the moment they haven't got much of a portfolio and nothing new so patent value is pretty minimal

Peter I never considered the dispute important. Win or lose it's a better outcome for the SP than at the moment as markets don't like unknowns. What's important is NCYTs ability to repaid costs if they lose out of future revenue. At the moment revenue is negative so we couldn't make payments or borrow cheaply and even a dispute win doesn't matter, NCYT would just be going broke slower atm. That's what will affect the SP after the settlement, bad or really bad with no revenue stream or good or really good with revenue.

Ventura, that's what I was trying to say, but failing. I'm guessing £1 a share fair value, but shareholders would want £4 a share to agree a sale, so a potential bidder needs to see an extra £3 a share in potential/add-on value. That's a lot of add-on value!

Key facts for NCYT

NCYT is mostly now comprised of Primer Design and IT-IS, they cost circa £20mm, and I think they have stated most revenue will be from Primer Design for the foreseeable.

NCYT is currently losing money , but it is cost cutting too.

NCYT has ~£100mm cash in hand

The break-up value of NCYT is probably no more than £30mm + cash in hand.

NCYT has no major shareholders to negotiate with.

Right here and now I'd value NCYT slightly south of £110mm as fair value to a bidder.
But also right here and now I can't see shareholders agreeing to such a low offer.

So a Bidders offer to T/O NCYT needs to reflect it's future potential to a new owner, but, the gulf between a fair value offer and an acceptable offer is probably 2-300% approx £3+ a share instead of £1. Just can't see it.

PI, think they just got it wrong, their SP suffered (and hasn't really reacted positively to any m&a) their revenue was bad and they seem to have switched to buying other disties, which I guess will bring instant revenue.

It's Theradiag kit, gastro tests iirc, can't find what I read prev. but here's a trading update for 22

https://www.yahoo.com/now/theradiag-reports-2022-revenue-12-063000844.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAIMcO5oufJO3LAMHTGyVcXhjfeJE4tDeUujbyI4whWcek_b_TKcQUC0VmFtcRCQF58v_nEwyikQUV1g7ukv6rH5v0gv3LbRpxsEkhonBLGAF_Gjff8Eez8ITKXJoxAgSa1pbhZxE9J7Gd17aj8mPGVjZkimlwEKYkdXsPS16d3L3

"eographically, regarding Theranostics activity, Theradiag has continued to expand its export business, with growth of +19.2%, notably thanks to the development of sales in Spain, the United Kingdom and Germany. Activity was stable in the United States (-1%), where investment was reduced and the business model adjusted during the second half of 2022. Indeed, Theradiag is focusing on marketing its tests through a distributor in that country in order to improve profitability and lessen risks with the exemption of fixed costs. Lastly, in France, activity has resumed its positive momentum with sales growing by 3.2%."

Bio are exclusive euro distie

Bio have a trading update on 19th

https://www.boursorama.com/bourse/actualites/biosynex-succes-de-l-opa-sur-theradiag-2b6e828437e7c854e706cd30af15fb3d?symbol=1rPALBIO

relevant to NCYT as Bio had their kit on trial at several NHS sites last year

Biosynex will distribute Credo Diagnostic's Covid detection system in the UK

"BIOSYNEX and Credo Diagnostics have recently strengthened their collaboration by signing an exclusivity agreement for an extended territory including the United Kingdom. Thanks to the acquisition of BHR in May 2022, BIOSYNEX now has a direct sales force in the United Kingdom and anticipates a significant deployment of the VitaPCRTM systems in this country which is at the forefront of Point-of-Care diagnostic solutions."

https://www.boursorama.com/bourse/actualites/biosynex-distribuera-le-systeme-de-detection-du-covid-de-credo-diagnostic-au-royaume-uni-c648d688cc76c6cc8b37bcaad2c1becb?symbol=1rPALBIO

SP might be a bit wobbly on Monday

1.4 billion, and the 60k is suspect, I think the prediction is 15-25mm by April. The problem isn't deaths (except for overstretched crematoriums) and it's not just strain on the health system, it's lost working days, businesses are struggling to remain open due to staff illness

No PI. The £10mm R&D budget means (apart from external costs such as materials or running trials) is that £10mm worth of salaries and lab time will be spent/allocated on R&D work and not something else. But if it wasn't spent on R&D it would be spent elsewhere on different projects because the staff and labs exist and need to be paid regardless of what they are doing. It's moving costs from one column to another in a spreadsheet

Please no more covid rns

Hoping it doesn't see 70p again. But...,

Holding up well

will it be bigger money earner than TATA PLC or Clonit though, fingers crossed

I mean.....

Whoops meant Google it wbafc.

normal service is resumed

You do understand that in the event of a takeover you actually don't get to keep your shares. It is the shareholder that is gotten rid of. And now would be a rotten time for either party in a T/O I mean what's a fair price for a takeover, what would the SP go to. Any T/O in the near term will be a reverse T/O and NCYT is ripe for that to happen.

Also the BoD isn't weak, it's just mostly the wrong BoD, IIRC they all have good CVs but also a blue chip background, hired when NCYT thought it was going straight to a 100mm a year ++. But it went the opposite way (for now at least) and they don't know how to run small companies. It's affected their careers as well

not bouncing much, but not sliding much. So nice if it could hang on to a £1 floor.